60 Degrees Pharmaceuticals, Inc.
SXTP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001946563
No open-market purchases or sales by 60 Degrees Pharmaceuticals, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $614.8K in total; no superinvestor holds it.
Other share classesSXTPW
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 3:04 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | – | – |
| Revenue | $1.01M | $607.6K | $253.6K |
| Cost of revenue | $781.7K | $384.8K | $474.6K |
| Gross profit | $223.8K | $222.8K | -$221.0K |
| Operating expenses | $8.39M | $10.0M | $4.93M |
| Research and development | $2.11M | $4.99M | $691.8K |
| Selling, general and administrative | $6.28M | $5.02M | $4.24M |
| Operating income | -$7.76M | -$9.71M | -$5.15M |
| Interest expense | – | $0 | $2.29M |
| Income tax | $0 | $250 | $250 |
| Net income | -$7.37M | -$7.95M | -$3.77M |
| EPS, basic | $-11.73 | $-18.55 | $-0.99 |
| EPS, diluted | $-11.73 | $-18.55 | $-0.99 |
| Weighted shares, basic | 670.2K | 454.6K | 3.96M |
| Weighted shares, diluted | 670.2K | 454.6K | 3.96M |
| Margins and growth | |||
| Gross margin | 22.3% | 36.7% | -87.1% |
| Operating margin | -771.6% | -1599.0% | -2032.8% |
| Net margin | -732.5% | -1308.0% | -1485.1% |
| Revenue growth, year over year | +65.5% | +139.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | – | – |
| Cash and equivalents | $1.51M | $1.66M | $2.14M |
| Short-term investments | $1.24M | $1.73M | – |
| Accounts receivable | $509.6K | $486.7K | $231.3K |
| Inventory | $656.9K | $442.8K | $466.2K |
| Total current assets | $4.90M | $5.39M | $7.24M |
| Property, plant and equipment | $246.4K | $149.8K | $57.8K |
| Intangible assets | $224.4K | $157.1K | $227.3K |
| Total assets | $5.37M | $5.76M | $7.78M |
| Short-term debt | $8.77K | $8.77K | – |
| Total current liabilities | $1.84M | $1.66M | $2.84M |
| Long-term debt | $144.0K | $150.0K | $150.0K |
| Total liabilities | $1.99M | $1.80M | $2.99M |
| Shareholders' equity | $3.38M | $3.96M | $4.80M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | – | – |
| Operating cash flow | -$6.85M | -$5.65M | -$4.54M |
| Capital expenditures | $139.9K | $103.8K | $57.6K |
| Free cash flow | -$6.99M | -$5.75M | -$4.60M |
| Depreciation and amortization | $43.3K | $11.7K | – |
| Stock-based compensation | $456.3K | $3.61M | $212.6K |
| Investing cash flow | $254.9K | -$1.89M | -$115.9K |
| Financing cash flow | $6.44M | $7.05M | $6.47M |
| Net change in cash | -$149.3K | -$483.1K | $1.88M |
| Ratio | |||
| Stock-based compensation, % of revenue | 45.4% | 593.9% | 83.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 14, 2026 | 3.52M | −14.3% | SEC |
| May 15, 2026 | 2.66M | +80.5% | SEC |
| Mar 30, 2026 | 2.64M | +79.0% | SEC |
| Nov 13, 2025 | 4.23M | +84.1% | SEC |
| Aug 13, 2025 | 4.10M | +132.1% | SEC |
| May 15, 2025 | 1.47M | −87.9% | SEC |
| Mar 27, 2025 | 1.47M | −87.3% | SEC |
| Nov 14, 2024 | 2.30M | −60.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.